Structurally distinct membrane-associated and soluble forms of GH-binding protein in the mouse.

It has previously been shown that the large increase in GH-binding capacity of mouse liver microsomes during pregnancy is due largely to an increase in the amount of GH-binding protein (GHBP), with a more modest increase in GH receptor (GHR). Here we show that mouse liver GHBP is predominantly present as a membrane-associated protein structurally distinct from the soluble form of GHBP present in serum. Liver GHBP is associated with both intracellular membranes and the plasma membrane. Membrane-associated GHBP and soluble GHBP appear to be identical polypeptides distinguished by the addition of different N-glycans to asparagine residues. The pattern of release of GHBP from membranes by various treatments indicates that GHBP associates with membranes through noncovalent interactions with one or more membrane protein, but not with GHR. Covalent crosslinking provides evidence for several GHBP-associated membrane polypeptides, with molecular masses ranging from 58 kDa to over 200 kDa. These studies in the mouse and similar studies in the rat suggest that GHBP is an important cell-surface receptor for GH in the liver of these species. We postulate that an arginine-glycine-aspartic acid sequence found on rat and mouse GHBP but absent in other species is responsible for the association of GHBP with the plasma membrane by binding to one or more integrins on the surface of liver cells.

Transcriptional upregulation of hepatic GH receptor and GH-binding protein expression during pregnancy in the mouse.

In the mouse, GH-binding protein (GHBP) and GH receptor (GHR) are encoded by a single gene via alternative splicing. We previously demonstrated that the steady-state levels of the GHR and GHBP mRNAs are significantly elevated in mouse liver during pregnancy. Hepatic GHR and GHBP mRNAs are associated primarily with one of two different 5' untranslated regions (5' UTRs), designated 5' UTR Liver1 (L1) and Liver2 (L2). Distinct promoters associated with each of these 5' UTRs have recently been characterized. In the present study, we have investigated the role of transcriptional activation in the pregnancy-induced upregulation of GHR and GHBP mRNAs in liver. We also report on the relative contribution of the 5' UTR L1 and 5' UTR L2 promoters to the hepatic expression of the GHR/GHBP gene in the liver. Our approach was to compare, by ribonuclease protection assay (RPA), GHR/GHBP transcript levels in hepatic nuclear and total cellular RNA samples from virgin and late-pregnant mice. In these RPAs we utilized riboprobes that were complementary to the coding region of GHR/GHBP transcripts, as well as to the two noncoding, alternative first exons 5' UTR L1 and L2. When employing the coding region probe, RPAs revealed that the gestational increase in the levels of nuclear GHR/GHBP transcripts were statistically comparable with the increase in GHR/GHBP transcript levels in total cellular RNA. This finding suggests that enhanced transcriptional activity, rather than increased cytoplasmic half-life, is responsible for the upregulation of GHR/GHBP RNA in the pregnant liver. In RPAs utilizing the noncoding region probes, both nuclear and total cellular GHR/GHBP transcripts associated with 5' UTR L1 were significantly upregulated in late-pregnant as compared with virgin mice. In contrast, the levels of both nuclear and total GHR/GHBP transcripts associated with 5' UTR L2 were comparable between nonpregnant and pregnant animals. Moreover, 5' UTR L2-containing transcripts were present at levels that were only 3-5% of the 5' UTR L1-associated transcripts in the late-pregnant liver. Thus, we conclude that the gestational upregulation of the GHR/GHBP gene in the mouse liver can be ascribed to the significantly enhanced transcriptional activity of the 5' UTR L1 promoter.

Growth hormone (GH) receptor and GH-binding protein messenger ribonucleic acids with alternative 5'-untranslated regions are differentially expressed in mouse liver and placenta.

Two 5'-untranslated regions (5'UTRs) with distinctly different sequences, designated 5'UTR L1 and 5'UTR L2, were obtained by amplification of complementary DNA from mouse liver and placenta with primers complementary to sequences from the hormone-binding domain common to GH receptor (GHR) and GH-binding protein (GHBP) messenger RNAs (mRNAs). The presence of an open reading frame in the 5'UTR L2 and the high GC content of this sequence suggest that mRNAs containing this 5'UTR may be translated with a lower efficiency than those containing 5'UTR L1. Expression studies showed that 5'UTR L1 and 5'UTR L2 are present in GHR and GHBP mRNAs in both tissues. However, the relative expression of the two 5'UTRs differs between liver and placenta and in liver from different physiological states. The different expression patterns of the L1 and L2 5'UTRs predict that the corresponding 5'-noncoding exons of the GHR/GHBP gene are associated with different regulatory elements. The expression patterns of the 5'UTRs also indicate that there is a linkage between the 5'UTR present in GHR/GHBP gene transcripts and the alternative splicing of these transcripts to yield either GHR or GHBP mRNAs. The 5'-noncoding exon used for transcription of the GHR/GHBP gene, therefore, may be involved in regulating both the ratio of GHR to GHBP transcripts and the efficiency of translation of these transcripts. Transcription from the different 5'-noncoding exons of the GHR/GHBP gene thus may be a critical element in the regulation of the expression of GHR and GHBP and thereby in the control of the responses of different tissues to GH.

Mouse growth hormone-binding protein and growth hormone receptor transcripts are produced from a single gene by alternative splicing.

Serum contains a soluble growth hormone-binding protein which is produced in some species by proteolytic cleavage of the extracellular domain of the growth hormone receptor. The hypothesis that a growth hormone-binding protein messenger RNA is produced in other species by alternative splicing of nascent growth hormone receptor transcripts was confirmed by analysis of the mouse growth hormone receptor gene. An exon that encodes the hydrophilic tail of the binding protein is located between an exon encoding the final portion of the hormone binding domain and an exon encoding the hydrophobic transmembrane domain of the receptor.

Interleukin 6 inhibits mouse placental lactogen II but not mouse placental lactogen I secretion in vitro.

The mouse placenta produces several polypeptides belonging to the prolactin-growth hormone gene family, including mouse placental lactogen (mPL) I and mPL-II. The present study was undertaken to determine whether the secretion of mPL-I and mPL-II is regulated by interleukin 6 (IL-6), which is present in the placenta and has previously been reported to stimulate the secretion of pituitary members of this gene family. Effects of human and mouse IL-6 on mPL-I and mPL-II secretion were examined in primary cultures of placental cells from days 7, 9, and 12 of pregnancy. IL-6 caused a dose-dependent reduction in the mPL-II concentration in the medium of cells from days 9 and 12 of pregnancy but did not affect the mPL-II concentration in the medium of cells from day 7 of pregnancy or the mPL-I concentration in the medium of cells from days 7 or 9 of pregnancy. The lowest concentration of human IL-6 that significantly inhibited mPL-II secretion was 250 pM. The effect of IL-6 on the mPL-II concentration in the medium was due primarily to inhibition of mPL-II synthesis, which resulted at least partly from a decrease in the steady-state level of mPL-II mRNA. These data raise the possibility that IL-6 may regulate mPL-II production after midpregnancy in vivo.

Growth hormone receptor and growth hormone-binding protein messages in mouse placenta contain the exon analogous to human exon 3.

Growth hormone receptor (GHR)-encoding messages from the human placenta and other tissues have been recently characterized by several investigators. Of particular interest is the finding that exon 3 is deleted from the mRNA encoding GHR in human placenta, but not in maternal tissues. We have used a reverse transcriptase-polymerase chain reaction (RT-PCR) technique to amplify the distinct mRNAs encoding GHR and GH-binding protein (GHBP) in the mouse placenta and liver, followed by restriction analysis, to determine whether an analogous deletion exists in these mRNAs. The restriction analysis and sequencing of the PCR products shows that the mRNAs encoding GHBP and GHR in the mouse placenta do not have a deletion analogous to that found in human placental GHR mRNA.

Gonadotropin-releasing hormone-induced accumulation of follicle-stimulating hormone beta-subunit messenger ribonucleic acid in adenohypophysial cells developing in an ectopic position.

We investigated the influence of LHRH on the accumulation of FSH beta messenger RNA (mRNA) in anterior pituitary glands removed from hamster pups less than 36 h old and transplanted beneath the renal capsules of adult male hamsters (hosts). Three experiments were performed in which some hosts were injected sc with LHRH (1 microgram/injection) and others were injected with vehicle. Injections were begun in the afternoon of the day of transplantation (day 1) and were given at 0800 and 1700 h for 6 days and at 0800 h on the eighth day. An additional experiment was performed in which adult male hamsters not bearing allografts were injected with the same regimen of LHRH or vehicle. The hamsters were decapitated on the eighth day of the study, 2 h after the last injection. The allografts, adenohypophyses of the hosts, adenohypophyses of hamsters without allografts, and adenohypophyses of normal adult male rats were removed and frozen on dry ice immediately. Additionally, adenohypophyses were collected from hamster pups less than 36 h old and 8 and 15 days of age. Total RNAs from some pooled specimens were electrophoresed on a formaldehyde-agarose gel. After transfer to Nytran, the RNAs were hybridized sequentially to complementary DNAs for rat FSH beta and hamster beta-actin. The rat FSH beta complementary DNA probe hybridized to a single RNA (approximately 1.7 Kb) in rat adenohypophyses. It predominantly hybridized to RNA of approximately 1.7 Kb from hamster adenohypophyses. Sometimes it hybridized to RNAs ranging in size from 0.5 Kb to 1.7 kb. The hybridization signals for all samples obtained from dot blot analyses were quantitated and normalized to the signals for beta-actin. The hybridization signals obtained from adenohypophyses of hamsters of different ages increased from 36 h of age to adulthood. The hybridization signal obtained from adenohypophyses of hamsters less than 36 h old (the same age as the donor hamsters) was similar to the hybridization signal obtained from allografts in vehicle-treated hamsters. The relative levels of FSH beta mRNA in allografts of LHRH-treated hosts were: 1) greater than the relative levels in adenohypophyses of hamsters less than 36 h old (P less than 0.05) and in allografts in vehicle-treated hamsters (P less than 0.05), 2) greater than the relative levels in adenohypophyses of 8-day-old hamsters (P less than 0.05), and 3) not different compared to the relative levels in adenohypophyses of 15-day-old hamsters and adult male hamsters.(ABSTRACT TRUNCATED AT 400 WORDS)

Sequence and expression of hamster prolactin and growth hormone messenger RNAs.

Complementary DNAs encompassing the complete protein-encoding regions for PRL and GH of the Syrian Golden hamster were sequenced and used as probes to examine the expression of hamster PRL and GH messenger RNA (mRNA)s. The complementary DNA (cDNA) for hamster PRL encodes a 226 amino acid preprotein which, by analogy to rat and mouse PRLs, is predicted to be processed to yield a 197 amino acid secreted protein. The hamster GH cDNA codes for a 216 amino acid preprotein predicted to yield a 190 amino acid secreted protein. Both hamster proteins are highly homologous to the corresponding rat and mouse hormones. For the secreted proteins, hamster PRL has 82% amino acid identity with rat PRL and 72% identity with mouse PRL. The rodent GH sequences are more strongly conserved, with 97-98% sequence identity between hamster, rat, and mouse GHs. The hamster hormones contain the highly conserved cysteine residues (six in hamster PRL and four in hamster GH) present in other mammalian PRLs and GHs. Neither hamster PRL nor hamster GH contains cysteine residues corresponding to the unique pair of cysteines present in hamster placental lactogen-II. The hamster PRL and GH cDNAs each hybridized to pituitary mRNAs of approximately 1 kilobase. Expression of hamster PRL and GH mRNAs was compared between 2 days of the estrous cycle (proestrus and estrus) and early, mid, and late pregnancy (days 5, 10, and 15). PRL mRNA levels in cycling hamsters were approximately 50% of those in pregnant hamsters. No other significant differences in PRL or GH mRNA levels were observed, suggesting that differences in circulating PRL and GH protein levels during the estrous cycle and pregnancy in the hamster are the result largely of factors other than changes in mRNA levels.

Purification and characterization of mouse decidual calcyclin: a novel stimulator of mouse placental lactogen-II secretion.

The effects of secretagogue(s) from mouse decidual tissue on the release of mouse placental lactogen-II (mPL-II) were studied. Decidual tissue was obtained from 10- and 11-day-pregnant mice. The tissue was homogenized, extracted, and the tissue extract was made 50% saturated with ammonium sulfate. Both the precipitate and supernatant were tested for their ability to stimulate mPL-II release from cultured trophoblasts. The supernatant contained an activity to stimulate the release of mPL-II. This activity was further purified using column chromatography. The purification resulted in isolation of a protein with a mol wt of 20 K as estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions and 6 K under reducing conditions. Further characterization of this protein showed that it binds calcium and has an amino acid sequence that is highly homologous with calcyclin expressed in mouse embryonic fibroblast cells and with calcyclin from other species. This protein was designated mouse decidual calcyclin. Antiserum was raised against the purified decidual calcyclin for development of an RIA and for immunoblots. Western blots of various mouse tissue extracts and mouse serum from different physiological stages showed that the concentration of calcyclin was highest in decidual tissue. Detectable levels were found in extracts from trophoblast, lung, and stomach, but the concentrations in these tissues were about 100 times lower than in decidua. Decidual calcyclin was not detectable in mouse serum. Cultured decidual cells released calcyclin into the medium. On average, this release was about 7.8 ng/micrograms DNA.24 h. The rate of release did not change significantly during 4 days of culture. The ratio of calcyclin in cells per calcyclin released during 24 h averaged 2.3 and did not change significantly during the culture period. The purified decidual calcyclin stimulated the release of mPL-II from cultured trophoblasts in a dose-dependent manner at concentrations from 0.01 to 1 microgram/ml. The maximum stimulation averaged about 1.5 times above control. It is concluded that decidual calcyclin may be of physiological importance for the regulation of mPL-II secretion.

Immunohistochemical co-localization of placental lactogen II and relaxin in the golden hamster (Mesocricetus auratus).

Two hormones with lactogenic activity are produced by the hamster placenta during the second half of pregnancy. One of these hormones, hamster placental lactogen II (haPL-II), has been well characterized; however, its cellular source is not known. In the present study, haPL-II was localized in placental tissues using a specific antibody and the avidin-biotin-peroxidase immunohistochemical technique. Because relaxin has been localized in the hamster placenta, it was of interest to determine if haPL-II and relaxin are localized in the same cells. haPL-II immunoactivity was observed in primary and secondary giant trophoblast cells of the placenta on Days 12, 14, and 15 of pregnancy. On Day 15 positive staining was also observed in large cells located within mesometrial arteries and in eosinophilic bodies associated with degenerating sheathed arteries of the decidua basalis. haPL-II-positive staining was not observed in placentae from Days 8 or 10 of pregnancy. On Day 14, haPL-II was colocalized with relaxin in 75% of the giant trophoblast cells observed. Therefore, it is probable that these hormones are synthesized and secreted by the same cell.

Hamster placental lactogen-II contains a structural feature unique among the growth hormone-prolactin-placental lactogen family.

Sequence analysis of cDNA for hamster placental lactogen-II (PL-II) revealed that while this protein has a high degree of sequence homology to mouse and rat PL-II it contains a pair of cysteine residues not present in the mouse and rat proteins or in any other known member of the GH-PRL-PL protein family. This unique pair of cysteine residues may be responsible for the extreme tendency of hamster PL-II, compared to other members of the GH-PRL-PL family, to form disulfide-bonded hormone-serum protein complexes.

Mouse placental lactogen-I: RIA and gestational profile in maternal serum.

A RIA for mouse placental lactogen-I (mPL-I) was developed using recombinant mPL-I as the standard, radioligand, and antigen for antiserum production. Displacement curves for dilutions of serum and placental extracts from pregnant mice were parallel to the recombinant mPL-I standard curve. Serum from male and nonpregnant female mice and high concentrations of mouse PRL, GH, PL-II, proliferin, and proliferin-related protein did not cross-react in the assay. mPL-I appeared in maternal serum on day 6 of pregnancy. Its concentration remained low until day 8 and them increased to a very large peak on days 9-11 (maximum concentration, approximately 8 micrograms/ml). The mPL-I concentration declined after day 11, but the hormone could be detected at low concentration in maternal serum until the end of pregnancy. On day 10 of pregnancy, the mPL-I concentration of maternal serum was correlated with litter size. Fractionation of serum from 10-day pregnant mice by size exclusion chromatography indicated the absence of high mol wt forms of mPL-I in the circulation.

High molecular weight forms of placental lactogen: evidence for lactogen-macroglobulin complexes in rodents and humans.

Gel filtration chromatography of maternal plasma from late pregnant hamsters demonstrated that approximately 90% of hamster placental lactogen-II (PL-II) is present as high mol wt (Mr) forms. A major peak of immunoactive hamster PL-II with a Mr of 600,000 and a smaller peak (Mr, 210,000) were observed. The major high Mr form of hamster PL-II in plasma had a Mr of 360,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). High Mr forms also predominate in placental extracts, but differ from the plasma forms. 125I-Labeled monomeric hamster PL-II (Mr, 22,000) formed a disulfide-bonded complex (Mr, 720,000 by gel filtration and 360,000 by SDS-PAGE) when incubated in vitro with serum of male, nonpregnant female, or pregnant hamsters. The in vitro complex was also formed with unlabeled hamster PL-II. Similar high Mr complexes were formed, but to a lesser extent, when 125I-labeled mouse PL-II and human PL were incubated with the homologous late pregnant serum. High Mr complexes (Mr, 360,000 by SDS-PAGE) were also formed when the three 125I-labeled PLs were incubated with purified human alpha 2-macroglobulin. The most prominent circulating high Mr form of hamster PL-II had a Mr similar to that of alpha 2-macroglobulin by both gel filtration and SDS-PAGE. In addition, it had a mobility similar to that of alpha 2-macroglobulin on nondenaturing polyacrylamide gels, and it was about 10% asparagine-linked carbohydrate by weight, as is alpha 2-macroglobulin. These similarities and the ability of hamster PL-II to form a disulfide-bonded complex with alpha 2-macroglobulin in vitro suggest that the major circulating form of PL-II in the hamster may be a disulfide-bonded complex of one or more PL monomers with alpha 2-macroglobulin or a related plasma protein. Similar complexed forms of PL may be present in mice and humans.

Antipeptide antibodies reveal structural and functional characteristics of rat placental lactogen-II.

The purpose of this investigation was to develop specific immunologic probes to rat placental lactogen-II (PL-II) and to use the immunologic probes to further characterize rat PL-II. Five oligopeptides corresponding to different regions of rat PL-II (amino acids 1-13, 56-70, 89-103, 107-118, 150-164) were chemically synthesized by solid phase methods and purified to homogeneity by reverse phase high performance liquid chromatography. The synthetic peptides were coupled to keyhole limpet hemocyanin (KLH) and the peptide-KLH conjugates were used to immunize rabbits. Antibody production was monitored by enzyme-linked immunoassay (EIA), electrophoresis and immunoblotting analyses. Each of the antipeptide antisera showed reactivity with the entire rat PL-II protein; however, the extent of the reactivities of each antiserum with rat PL-II was dependent on the conformational state of rat PL-H. Antisera directed to amino acids 56-70 showed the best reactivity toward each of the conformational states of rat PL-II tested. Antibodies generated to the entire rat PL-II protein specifically recognized the 56-70 amino acid sequence but showed limited reactivity with synthetic peptide corresponding to amino acids 1-13, 89-103, 107-118, and 150-164 of rat PL-II. Antisera to amino acids 56-70 of rat PL-II were specific for PLs as demonstrated by their recognition of rat PL-II, mouse PL-II and human PL and by their lack of reactivity with rat pituitary prolactin and growth hormone and with a series of other synthetic peptides to rat PL-II and rat prolactin-like protein-A. The immunorecognition of human PL was restricted to antipeptide antibodies directed to amino acids 56-70 of rat PL-II. The chemically synthesized peptides representing various regions of rat PL-II did not show significant interactions with prolactin receptors, and antisera directed to the peptides failed to interfere with the binding of either rat PL-II or human PL to prolactin receptors. In summary, we have generated a series of immunologic probes for studying the structure of rat PL-II. The sequence comprising amino acids 56-70 of rat PL-II was shown to make up at least part of an epitope for rat PL-II and to be a region of significant structural homology with mouse PL-II and human PL.

Biological, immunological, and binding properties of recombinant mouse placental lactogen-I.

Mouse placental lactogen-I (mPL-I) cDNA was inserted into a eukaryotic expression vector and introduced into Chinese hamster ovary cells. Cell lines that secrete high concentrations of mPL-I were isolated, and this glycoprotein was purified from the cell culture-conditioned medium. Recombinant mPL-I (mPL-Ir) is very similar to placental mPL-I (mPL-Ip) in its recognition by polyclonal antisera raised against either mPL-Ip or mPL-Ir, in displacing [125I]iodo-mPL-II from binding sites on mouse liver microsomal membranes, and in stimulating the synthesis of alpha-lactalbumin in primary cultures of mouse mammary epithelial cells. Structural comparison of mPL-Ir and mPL-Ip by sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicated that mPL-Ir comprises several proteins with mol wt ranging from 34.5-38K, while mPL-Ip consists of a similar set of proteins with mol wt ranging from 36.5-42K. Treatment of the two proteins with neuraminidase resulted in similar 2-4K decreases in mol wt. Treatment of mPL-Ip with peptide:N-glycosidase-F to remove asparagine-linked oligosaccharide chains resulted in the formation of 28K and 29K mol wt species, while treatment of mPL-Ir with the same enzyme yielded 28K and 28.5K mol wt products.

Pituitary factors regulating mouse placental lactogen-II secretion during the last half of pregnancy in mice.

Hypophysectomy of mice during the last half of pregnancy results in an increase in the maternal serum mouse placental lactogen-II (mPL-II) concentration. The present study was undertaken to isolate and identify the pituitary factors that regulate mPL-II. Administration of pituitary extracts from virgin and day 12 pregnant mice (five pituitaries per mouse, every 8 h, sc) and bilateral pituitary implants under the kidney capsule significantly inhibited the increase in the mPL-II concentration that occurs within 24 h after hypophysectomy on day 12 of pregnancy, which indicated that the pituitary secretes factors that regulate mPL-II. To characterize these factors biochemically, pituitaries from virgin female mice were incubated for 14 days, and the culture medium was pooled, concentrated, and then fractionated by gel exclusion chromatography on Sephadex G-100, followed by ion exchange chromatography on DEAE. The fraction from DEAE chromatography that contained predominantly mouse (m) GH as well as a very small amount of a substance with an approximate mol wt of 23K suppressed the posthypophysectomy rise in serum mPL-II. To determine whether purified PRL, GH, and the unknown 23K substance present in the active fraction from the DEAE column could suppress the posthypophysectomy rise in serum mPL-II, repeated injections and constant infusion of these substances were carried out in hypophysectomized mice. Repeated injections of purified mPRL and bovine (b) PRL and constant infusion of mPRL were without effect. Repeated injection of mGH at doses of 1 and 10 micrograms/mouse or of bGH at doses of 50, 150, and 450 micrograms/mouse were also not effective, but bGH injections at a dose of 5 mg/mouse suppressed the posthypophysectomy rise in serum mPL-II. Subsequently, two pools of mGH were prepared by ion exchange HPLC; mGH-A contained predominantly mGH as well as a very small amount of an unidentified 23K mol wt substance, and mGH-B contained only mGH. When mGH-A and mGH-B were infused at a constant rate into hypophysectomized pregnant mice, both suppressed serum mPL-II concentrations; there was no difference in activity between mGH-A and mGH-B. These results indicate that mGH, but not mPRL, regulates the serum PL-II concentration in the mouse. mPL-II secretion is under the inhibitory control of mGH, the concentration of which increases rapidly at the beginning of the last half of pregnancy.

Hamster placental lactogens: gestational profiles and high molecular weight forms.

We previously reported the purification of a lactogenic protein, hamster placental lactogen (haPL; now designated haPL-II) from late pregnant hamster placentas. In this study the lactogenic factors in maternal serum during the second half of pregnancy were measured using RIAs for haPL-II and haPRL and a RRA for total lactogenic activity. haPL-II was first detectable on day 10 of pregnancy and reached a maximal concentration [12.3 +/- 0.8 microgram/ml (mean +/- SEM); n = 6] on day 16 (term). PRL concentrations were relatively low during the second half of gestation. Significant amounts of lactogenic activity that could not be ascribed to haPL-II or haPRL were detected throughout this period, with maximal concentrations on days 10-12. Gel filtration chromatography of day 10 serum gave an apparent mol wt of 35,000 for this lactogenic factor. A lactogenic factor with a similar mol wt (37,000) was detected in an extract of day 10 placenta. This lactogenic factor was designated haPL-I. The most prominent forms of haPL-II in day 16 serum were several disulfide-bonded forms with mol wt greater than 200,000. Smaller quantities of lower mol wt forms, including monomeric haPL-II, were present, but circulated as noncovalently bound complexes with mol wt greater than 100,000. Complete conversion to monomeric haPL-II was found only after treatment with both sodium dodecyl sulfate and 2-mercaptoethanol. The high mol wt forms of haPL-II in maternal serum were composed of two different monomeric species of haPL-II.

Purification and partial characterization of prolactin from the California ground squirrel (Spermophilus beecheyi).

Prolactin (Prl) secreted by cultured ground squirrel (Spermophilus beecheyi) pituitaries (SbPrl) was purified by gel filtration on Sephadex G-100 and ion-exchange chromatography on Polybuffer Exchanger 94. Purification from culture medium from 190 pituitaries yielded 1.1 mg of purified SbPrl. The SbPrl has an apparent molecular weight of 27,000 by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate, an isoelectric point of 6.3, and does not contain any asparagine-linked carbohydrate. Purified SbPrl displaces 125I-labeled ovine Prl from binding sites on lactating rabbit mammary gland membranes and stimulates secretion of alpha-lactalbumin by cultured mouse mammary gland epithelial cells.